Apoquel oral therapy for canine pruritus has been made available to all UK vet practices on unlimited distribution.
Launched in 2015, Apoquel was in such high demand that Zoetis had to create an allocation system to ensure dogs that started using the product could remain on it for as long as their vet deemed appropriate.
Zoetis’ companion animal business unit director Ned Flaxman said: “We are very grateful to all our veterinary customers for bearing with us through this product shortage.
“Over the past 18 months we have incorporated a variety of safeguards to ensure Apoquel supply will better align with demand. We have reduced the length of time it takes to manufacture Apoquel and added further production capacity.
“It’s been a very long 18 months for everyone involved, but we’re looking forward to a very good Christmas and new year with Apoquel fully back in stock and we’d like to thank all our customers for their patience.”
Scratching an itch
Apoquel, a Janus kinase (JAK) inhibitor, provides pruritus relief and improves skin lesions.
It is designed to target the pruritogenic and pro-inflammatory pathways involved in the itch cycle. This, says Zoetis, allows effective reduction of allergic itch regardless of its cause as well as improvement of skin lesions associated with allergic skin diseases and atopic dermatitis.
- For more information visit www.zoetis.co.uk/apoquel